S. Raje

发表

Novel Application of the Two‐Period Microtracer Approach to Determine Absolute Oral Bioavailability and Fraction Absorbed of Ertugliflozin

D. Papadopoulos, A. Vaz, V. Sahasrabudhe, 2018, Clinical and translational science.

Disposition and Metabolic Profiling of [14C]Cerlapirdine Using Accelerator Mass Spectrometry

R. Obach, Louis Leung, Susanna Tse, 2014, Drug Metabolism and Disposition.

Evaluation of the Blood-Brain Barrier Transport, Population Pharmacokinetics, and Brain Distribution of Benztropine Analogs and Cocaine Using in Vitro and in Vivo Techniques

A. Newman, Jianjing Cao, N. Eddington, 2003, Journal of Pharmacology and Experimental Therapeutics.

Zonula occludens toxin increases the permeability of molecular weight markers and chemotherapeutic agents across the bovine brain microvessel endothelial cells.

A. Fasano, T. Dowling, C. Karyekar, 2003, Journal of pharmaceutical sciences.

Effects of Renal Impairment on the Pharmacokinetics of Abrocitinib and Its Metabolites

M. Dowty, B. Malhotra, Lisy Wang, 2021, Journal of clinical pharmacology.

Pharmacokinetics of Single-dose Ertugliflozin in Patients With Hepatic Impairment.

V. Sahasrabudhe, Kyle T. Matschke, Haihong Shi, 2018, Clinical therapeutics.

JPET #152975 1 TITLE: GSI-953 (begacestat): A novel, selective thiophene sulfonamide inhibitor of APP γ-secretase for the treatment of Alzheimer’s disease

T. Comery, B. Harrison, M. Pangalos, 2009 .

Influence of multidrug resistance (MDR) proteins at the blood-brain barrier on the transport and brain distribution of enaminone anticonvulsants.

K R Scott, D S Cox, H Gao, 2001, Journal of pharmaceutical sciences.

Enhancing the permeation of marker compounds and enaminone anticonvulsants across Caco-2 monolayers by modulating tight junctions using zonula occludens toxin.

K R Scott, D S Cox, H Gao, 2001, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.

Translational Research: Preclinical to Healthy Volunteer to Patient

J. Korth-Bradley, S. Raje, B. Tammara, 2017 .

Begacestat (GSI-953): A Novel, Selective Thiophene Sulfonamide Inhibitor of Amyloid Precursor Protein γ-Secretase for the Treatment of Alzheimer's Disease

T. Comery, B. Harrison, M. Pangalos, 2009, Journal of Pharmacology and Experimental Therapeutics.

Confirmatory population pharmacokinetic analysis for bapineuzumab phase 3 studies in patients with mild to moderate Alzheimer's disease

Kaori Ito, Chuanpu Hu, S. Raje, 2015, Journal of clinical pharmacology.

Safety, tolerability, pharmacokinetics and pharmacodynamics of ascending single and multiple doses of lecozotan in healthy young and elderly subjects.

A. Patat, D. Chassard, A. Płotka, 2009, British journal of clinical pharmacology.

Alteration in Indinavir Clearance During Interleukin‐2 Infusions in Patients Infected with the Human Immunodeficiency Virus

J. Metcalf, S. Vogel, S. Piscitelli, 1998, Pharmacotherapy.

Enhanced Permeability of Molecular Weight Markers and Poorly Bioavailable Compounds Across Caco-2 Cell Monolayers Using the Absorption Enhancer, Zonula Occludens Toxin

N. Eddington, D. Cox, N. N. Salama, 2002, Pharmaceutical Research.

Biomarker Exposure-Response Analysis in Mild-To-Moderate Alzheimer's Disease Trials of Bapineuzumab.

E. Liu, Kaori Ito, B. Corrigan, 2016, Journal of Alzheimer's disease : JAD.

Investigation of the potential pharmacokinetic and pharmaco‐dynamic drug interaction between AHN 1‐055, a potent benztropine analog used for cocaine abuse, and cocaine after dosing in rats using intracerebral microdialysis

J. Katz, Jianjing Cao, S. Raje, 2006, Biopharmaceutics & drug disposition.

A Positron Emission Tomography Study to Assess Binding of Lecozotan, a Novel 5‐Hydroxytryptamine‐1A Silent Antagonist, to Brain 5‐HT1A Receptors in Healthy Young and Elderly Subjects, and in Patients With Alzheimer's Disease

B. Långstrom, A. Patat, J. Paul, 2008, Clinical pharmacology and therapeutics.

P4-366: GSI-953, a potent and selective gamma-secretase inhibitor: Modulation of beta-amyloid peptides and plasma and cerebrospinal fluid pharmacokinetic/pharmacodynamic relationships in humans

L. Ereshefsky, J. Paul, M. Burczynski, 2008, Alzheimer's & Dementia.

Alzheimer's disease assessment scale-cognitive 11-item progression model in mild-to-moderate Alzheimer's disease trials of bapineuzumab

Kaori Ito, B. Corrigan, H. Brashear, 2015, Alzheimer's & dementia.

Pharmacodynamic Assessment of the Benztropine Analogues AHN-1055 and AHN-2005 Using Intracerebral Microdialysis to Evaluate Brain Dopamine Levels and Pharmacokinetic/Pharmacodynamic Modeling

A. Newman, J. Katz, Jianjing Cao, 2005, Pharmaceutical Research.

Concomitant blockade of 5-HT1A receptor and 5-HT transporter: Use of the Hunter Serotonin Toxicity Criteria in a clinical pharmacology study

A. Płotka, S. Chalon, L. Schechter, 2008, European Neuropsychopharmacology.

Alzheimer's disease progression model using disability assessment for dementia scores from bapineuzumab trials

Kaori Ito, B. Corrigan, H. Brashear, 2015, Alzheimer's & dementia.

Concomitant blockade of 5-HT1A receptor and 5-HT transporter: Use of the Hunter Serotonin Toxicity Criteria in a clinical pharmacology study

A. Płotka, S. Chalon, L. Schechter, 2008, European Neuropsychopharmacology.

Formes dosifiees pharmaceutiques et compositions associees

S. Raje, K. Ghosh, Arwinder Nagi, 2006 .